The past 12 months or so have seen Calliditas Therapeutics AB attract a Chinese partner, start a Phase III study of its lead product, and conduct a follow-on financing to its June 2018 IPO. All of this has improved business options for the Swedish biotech and, in particular, “the capital has given us flexibility,” noted Calliditas’s CEO, Renée Aguiar-Lucander.
But possibly of greater significance for Calliditas are recent changes to the design of the Phase III study of its lead investigational product, Nefecon (budesonide, targeted-release capsules), which might allow marketing approval and patient
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?